产品名称
Indomethacin, A non-steroidal anti-inflammatory, cell permeable, antipyretic agent.
Quality Level
description
Merck USA index - 14, 4968
assay
≥98% (by assay)
form
powder
potency
740 nM IC50
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white to off-white
solubility
ethanol: 20 mg/mL
shipped in
ambient
storage temp.
10-30°C
SMILES string
Clc1ccc(cc1)C(=O)[n]2c3c(c(c2C)CC(=O)O)cc(cc3)OC
InChI
1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
InChI key
CGIGDMFJXJATDK-UHFFFAOYSA-N
General description
A cell-permeable, non-steroidal anti-inflammatory, anti-pyretic agent. Non-selective cyclooxygenase (COX) inhibitor (IC50 = 740 nM for COX-1; IC50 = 970 nM for COX-2). Inhibits phospholipase A2 (IC50 = 145 µM). Reported to reduce Aβ42 levels independently of COX activity.
A non-steroidal anti-inflammatory, cell permeable, antipyretic agent. Non-selective COX inhibitor (IC50 = 740 nM for COX-1; IC50 = 970 nM for COX-2). Inhibits phospholipase A2 (IC50 = 145 µM). Strongly inhibits insoluble transthyretin (TTR) amyloid fibril formation and suppresses production of Aβ-peptide and secreted form of APP by inhibition of APP mRNA levels in NG108-15 cells.
Biochem/physiol Actions
Cell permeable: yes
Product does not compete with ATP.
Reversible: no
Other Notes
Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Kodoyama, K., et al. 2001. Biochem. Biophys. Res. Commun.281, 483.
Weggen, S., et al. 2001. Nature414, 212.
Kalgutkar, A.S., et al. 2000. Proc. Natl. Acad. Sci. USA97, 925.
Klabunde, T., et al. 2000. Nat. Struct. Biol.7, 312.
Futaki, N., et al. 1994. Prostaglandins47, 55.
Futaki, N., et al. 1994. Prostaglandins47, 55.
Stevenson, K.M., and Lumbers, E.R. 1992. J. Dev. Physiol. 17, 257.
Oliw, E. 1980. Prostaglandins19, 271.
Weggen, S., et al. 2001. Nature414, 212.
Kalgutkar, A.S., et al. 2000. Proc. Natl. Acad. Sci. USA97, 925.
Klabunde, T., et al. 2000. Nat. Struct. Biol.7, 312.
Futaki, N., et al. 1994. Prostaglandins47, 55.
Futaki, N., et al. 1994. Prostaglandins47, 55.
Stevenson, K.M., and Lumbers, E.R. 1992. J. Dev. Physiol. 17, 257.
Oliw, E. 1980. Prostaglandins19, 271.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Highly Toxic & Carcinogenic / Teratogenic (I)
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 1 Oral
存储类别
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
K Kadoyama et al.
Biochemical and biophysical research communications, 281(2), 483-490 (2001-02-22)
Cyclooxygenase (COX) synthesizes bioactive prostaglandins from arachidonic acid, and there are COX-1 and COX-2 isoforms with distinct pathophysiological functions. Recent studies demonstrated that COX-2 expression was up-regulated in the brain of patients with Alzheimer's disease. We established mouse neuroblastoma x
K M Stevenson et al.
Journal of developmental physiology, 17(6), 257-264 (1992-06-01)
The effects of indomethacin (10 mg/kg i.v. to the ewe and 12 mg/kg i.v. to the fetus) were examined in 8 chronically catheterized fetal sheep (117-138 days gestation). These doses suppressed fetal 6-keto-prostaglandin F1 alpha and thromboxane B2 levels. Fetal
Sai Koung Ngeun et al.
Biology, 13(2) (2024-02-23)
The myogenic differentiation potential of MSCs is a key factor in their potential use as a cell source for muscle tissue repair and regeneration. Additionally, evaluating the immunomodulatory properties of MSCs is important to highlight their potential for regulating inflammation
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 405268-10GM | 04055977188493 |
